Solifenacin Succinate Tablets — Class II drug recall D-0660-2021
Terminated recall by CIPLA, reported 2021-07-21, distributed nationwide. CGMP Deviations
| Recall number | D-0660-2021 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | CIPLA, Warren, NJ, United States |
| Recall initiated | 2021-06-10 |
| Classified | 2021-07-15 |
| Reported by FDA | 2021-07-21 |
| Terminated | 2024-01-10 |
| Distributed | Nationwide (US) |
| Quantity | 7,228 bottles |
| Reason classes | cgmp |
| NDC | 69097-0261-02 |
| Lot numbers | GG90819 |
| Expiration dates | 2021-06 |
Product
Solifenacin Succinate Tablets, 10 mg, 30-count bottles, Rx Only, Manufactured by: Cipla Ltd., Verna, Goa, India Manufactured for Cipla USA, Inc. 1560 Sawgrass Corporate Parkway, Suite 130, Sunrise, FL, 33323, NDC 69097-261-02.
Reason for recall
CGMP Deviations
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0660-2021. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.